Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial

Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial

Background: A blood-stage Plasmodium falciparum malaria vaccine would provide a

Acceptability of the R21/Matrix-M malaria vaccine alongside existing malaria interventions in the trial context

International audience Background The R21/Matrix-M malaria vaccine has been shown to

R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial

Introduction: The recently licenced R21/Matrix-M vaccine induces a protective antibody response. In

R21/Matrix-M Malaria Vaccine Uptake and Dose Completion Among Rural Niger Delta Children

Rationale: The successful deployment of malaria vaccines requires not only achieving initial vaccine

A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria

Abstract Background The clinical development of a single encounter treatment for uncomplicated malar